EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Machine Learning‐Optimized Immunogenic Cell Death Signature Reveals Tumor Immunogenicity and the Immunotherapy Response of Pancancer

Li Qiu, Danqing Huang, Yuening Zhang, Yingying Zhou, Ming Luo, Chengdong Zhang, Ying Huang, Mingyuan Zou, Wenlong Lu, Hui Liu, Shaowei Liu, Haoyang Huang und 11 weitere

MedComm – Future Medicine · 2025-12 · 4 (4)

DOI: 10.1002/mef2.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm – Future Medicine, online erschienen am 15.10.2025. Verfasst von Li Qiu und 22 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor immunogenicity determines their response to immune checkpoint inhibitors (ICIs), but the mechanisms governing pancancer immunogenicity remain incompletely understood. A further critical barrier to developing reliable predictive biomarkers is data set shift, which undermines model generalizability. Here, we address these challenges by developing a novel adversarial validation (AV)‐integrated machine learning framework, focusing on immunogenic cell death (ICD)‐related gene signatures (ICDRSs). We designed three AV‐based strategies to mitigate data set shift and validate the efficacies across multiple machine learning algorithms. Using dual‐modal data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), four optimal AV‐based classifiers (e.g., GradientBoosting, XGBoost, LGBM, and CatBoost) were screened, which effectively reduced inter‐cohort shift, enhancing both accuracy and robustness of downstream analysis. We identified novel risk/protective ICDRSs that strongly predicted patient survival and tumor immunogenicity across cancers. High‐risk ICDRSs correlated with immune‐exclusive microenvironments marked by impaired antigen presentation and aberrant tumor‐associated macrophage development, as revealed by single‐cell RNA sequencing. Validation across 13 ICI‐treated cohorts revealed the capacity of ICDRSs for anti‐PD‐1 nonresponse. Mechanistically, risk ICDRSs were linked to CD47‐SIRPA‐mediated immune evasion and proliferative macrophage subsets with terminal dysfunction. This study advances understanding of tumor immunogenicity, provides novel biomarker development tools, and supports personalized cancer immunotherapy decision‐making.

Zitieren

APA

Qiu, L., Huang, D., Zhang, Y., Zhou, Y., Luo, M., Zhang, C., Huang, Y., Zou, M., Lu, W., Liu, H., Liu, S., Huang, H., Ye, K., Hui, Y., Tang, C., Yan, Z., Zhong, X., Luo, Z., Huang, H., …, & Liu, J. (2025). A Machine Learning‐Optimized Immunogenic Cell Death Signature Reveals Tumor Immunogenicity and the Immunotherapy Response of Pancancer. MedComm – Future Medicine, 4(4). https://doi.org/10.1002/mef2.70035

Vancouver

Qiu L, Huang D, Zhang Y, Zhou Y, Luo M, Zhang C, et al. A Machine Learning‐Optimized Immunogenic Cell Death Signature Reveals Tumor Immunogenicity and the Immunotherapy Response of Pancancer. MedComm – Future Medicine. 2025;4(4). doi:10.1002/mef2.70035

BibTeX
@article{Qiu2025,
  author = {Qiu, Li and Huang, Danqing and Zhang, Yuening and Zhou, Yingying and Luo, Ming and Zhang, Chengdong and Huang, Ying and Zou, Mingyuan and Lu, Wenlong and Liu, Hui and Liu, Shaowei and Huang, Haoyang and Ye, Kaiwen and Hui, Yuan and Tang, Cheng and Yan, Zilong and Zhong, Xi and Luo, Zhiguo and Huang, Hongxin and Zhou, Ming and Jia, Guangshuai and Leng, Qibin and Liu, Jun},
  title = {A Machine Learning‐Optimized Immunogenic Cell Death Signature Reveals Tumor Immunogenicity and the Immunotherapy Response of Pancancer},
  journal = {MedComm – Future Medicine},
  year = {2025},
  volume = {4},
  number = {4},
  doi = {10.1002/mef2.70035}
}
Kostenlos starten →